Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0IOQUU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Ab2 |
|||||
| Organization | ELI LILLY AND COMPANY |
|||||
| Synonyms |
Ab2
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Nectin-4 (NECTIN4) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTVGDTYYP
GSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAREWNGMDVWGQGTTVTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFL FPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTVGDTYYP
GSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAREWNGMDVWGQGTTVTVSS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
AASGFTFSSYDMH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
AIGTVGDTY
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
AREWNGMDV
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPDSLAVSLGERATINCKSSQSVLYNSNNKNYLAWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFYTTPYSFGQGTKVEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIVMTQSPDSLAVSLGERATINCKSSQSVLYNSNNKNYLAWYQQKPGQPPKLLIYWASTR
ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFYTTPYSFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSSQSVLYNSNNKNYLA
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
YWASTRES
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQFYTTPYS
Click to Show/Hide
|
|||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Half Maximal Effective Concentration (EC50)
|
0.05
|
nM
|
U266 (CD38-) cells | . | ||
|---|---|---|---|---|---|---|
| Antigen Expression | Positive Tissue factor expression (TF+++/++; >350,000 tissue factor molecules/cell) | |||||
| Antibody Function | Ab2 bound to Normal Human Epidermal Keratinocytes | |||||
| Antibody Antigen Binding Assay | Normal Human Epidermal Keratinocytes cells were used. Antibody binding was quantified via flow cytometry and both the EC50 of the binding curves. | |||||
| Antibody Activity Information 2 | [1] | |||||
|
Half Maximal Effective Concentration (EC50)
|
0.06
|
nM
|
NCI-H1781 cells | CVCL_1494 | ||
| Antigen Expression | Positive Tissue factor expression (TF+++/++; >350,000 tissue factor molecules/cell) | |||||
| Antibody Function | Ab2 bound to NCI-H1781 cells | |||||
| Antibody Antigen Binding Assay | NCI-H1781 tumor cells representing lower endogenous expression. Antibody binding was quantified via flow cytometry and both the EC50 of the binding curves. | |||||
| Antibody Activity Information 3 | [1] | |||||
|
Half Maximal Effective Concentration (EC50)
|
0.19
|
nM
|
SUM190PT tumor cells | CVCL_3423 | ||
| Antigen Expression | Positive Tissue factor expression (TF+++/++; >350,000 tissue factor molecules/cell) | |||||
| Antibody Function | Ab2 bound to SUM190PT tumor cells | |||||
| Antibody Antigen Binding Assay | SUM190PT tumor cells representing high endogenous expression. Antibody binding was quantified via flow cytometry and both the EC50 of the binding curves. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
JP2025011033A Ab2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Mean tumor colume±SEM |
72.57䔲.06 mm3
|
High nectin-4 expression (nectin-4 +++) | ||
| Method Description |
Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.
Click to Show/Hide
|
||||
| In Vivo Model | UMUC3 Nectin-4 clone F7 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Mean tumor colume±SEM |
124.95䔮.32 mm3
|
Moderate nectin-4 expression (nectin-4++) | ||
| Method Description |
Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.
Click to Show/Hide
|
||||
| In Vivo Model | MDAMB468 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0473 nM
|
Positive nectin-4 expression (nectin-4+++/++) | ||
| Method Description |
ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H1781 cells | CVCL_1494 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.07 nM
|
Positive nectin-4 expression (nectin-4+++/++) | ||
| Method Description |
ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
|
||||
| In Vitro Model | Bladder carcinoma | T24-human nectin-4 clone cells | CVCL_0554 | ||
US20250000991A1 Ab2 ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0836 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab7 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||
References